Fiche publication
Date publication
septembre 2026
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MALLARD Joris
Tous les auteurs :
Camilleri GM, Janvier E, Pigneur F, Mallard J, Marijnen P, Vidican P, Mouret-Bonzi M, Beltran EEM, Cotard O, Raynard B, Neuzillet C
Lien Pubmed
Résumé
Sarcopenia is defined as a loss of muscle mass and strength. It represents a frequent and multifactorial complication in patients with gastrointestinal cancers, resulting from the combined effects of malnutrition, chronic inflammation, metabolic alterations, and reduced physical activity level. Its assessment relies on a combined approach integrating imaging tools and functional tests. Computed tomography, widely available in oncology, represents the reference method for the evaluation of body composition, particularly skeletal muscle mass and quality. Functional tests allow assessment of muscle strength and physical performance. Sarcopenia, including sarcopenic obesity phenotype, has a major prognostic impact from localized disease to advanced stages, being associated with an increased risk of postoperative complications, reduced tolerance to anticancer treatments, and decreased survival. Its management should be early, personalized, and multimodal, combining nutritional support, adapted physical activity, and a global patient-centered approach. Prehabilitation programs illustrate the benefits of an integrated strategy, whereas pharmacological approaches remain limited to date. Thus, sarcopenia should be considered an essential component of the care pathway in gastrointestinal oncology.
Mots clés
Cancers digestifs, Complications, Computed tomography, Digestive cancers, Multimodal management, Obésité sarcopénique, Prise en charge multimodale, Sarcopenia, Sarcopenic obesity, Sarcopénie, Tomodensitométrie
Référence
Bull Cancer. 2026 09 17;:
